✦ LIBER ✦

Feasibility of cisplatin (DDP) + topotecan (TPT) combination as second and third line therapy in epithelial ovarian cancer (EOC)

✍ Scribed by N. Iedà; A. Lissoni; G. Zanetta; G. Caspani; F. Fei; G. Brancatelli; E. Marinetti; C. Patregnani

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cyclophosphamide (C), adriamycin (A) and

✍ N. Colombo; A. Epis; S. Chiari; F. Landoni; S. LoMonico; C. Mangioni; S. Gerardo 📂 Article 📅 1989 🏛 Elsevier Science 🌐 English ⚖ 154 KB

Phase II Trial of Topotecan, Carboplatin

✍ G. Bolis; G. Scarfone; A. Villa; F. Parazzini 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 29 KB

533 - Independent radiological review of

✍ S.J. Gwyther; M. Gore; W. ten Bokkel Huinink; S.Z. Fields; I. Hudson 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 378 KB

EORTC LCCG Phase II study of topotecan i

✍ Ardizzoni, A; Manegold, C; Debruyne, C; Gaafar, R; Buchholz, E; Dussenne, S; Leg 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 119 KB

Use of OvaRex(r) MAb-b43.13 as an immuno

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 161 KB

An open-label, single-arm Phase II study

✍ Peter G. Rose; Bradley J. Monk; Diane Provencher; Jean Hartney; Philippe Legenne 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 192 KB